Publications by Jochen Schwenk
Peer reviewed
Articles
[1]
A. Halama et al., "A roadmap to the molecular human linking multiomics with population traits and diabetes subtypes," Nature Communications, vol. 15, no. 1, 2024.
[2]
G. Wang et al., "BMI trajectories from birth to young adulthood associate with distinct cardiometabolic profiles," BMC Medicine, vol. 22, no. 1, 2024.
[3]
I. B. Kotliar et al., "Multiplexed mapping of the interactome of GPCRs with receptor activity-modifying proteins," Science Advances, vol. 10, no. 31, pp. 9959, 2024.
[4]
C. Fredolini et al., "Proteome profiling of home-sampled dried blood spots reveals proteins of SARS-CoV-2 infections," Communications Medicine, vol. 4, no. 1, 2024.
[5]
R. Eriksen et al., "The Association of Cardiometabolic, Diet and Lifestyle Parameters With Plasma Glucagon-like Peptide-1: An IMI DIRECT Study," Journal of Clinical Endocrinology and Metabolism, vol. 109, no. 9, pp. 1697-1707, 2024.
[6]
M. G. Andreassi et al., "A Longitudinal Study of Individual Radiation Responses in Pediatric Patients Treated with Proton and Photon Radiotherapy, and Interventional Cardiology : Rationale and Research Protocol of the HARMONIC Project," International Journal of Molecular Sciences, vol. 24, no. 9, pp. 8416, 2023.
[7]
R. Zenlander et al., "A wide scan of plasma proteins demonstrates thioredoxin reductase 1 as a potential new diagnostic biomarker for hepatocellular carcinoma," Scandinavian Journal of Gastroenterology, vol. 58, no. 9, pp. 998-1008, 2023.
[8]
O. FitzGerald, J. M. Schwenk and H. I. P. P. O. C. R. A. T. E. S. Consortium, "Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis," Therapeutic Advances in Musculoskeletal Disease, vol. 15, 2023.
[9]
R. L. Allesøe et al., "Discovery of drug–omics associations in type 2 diabetes with generative deep-learning models," Nature Biotechnology, vol. 41, no. 3, pp. 399-408, 2023.
[10]
M. J. Iglesias et al., "Elevated plasma complement factor H related 5 protein is associated with venous thromboembolism," Nature Communications, vol. 14, no. 1, 2023.
[11]
I. B. Kotliar et al., "Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins," Pharmacological Reviews, vol. 75, no. 1, 2023.
[12]
A. Mälarstig et al., "Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation," Nature Communications, vol. 14, no. 1, 2023.
[13]
A. A. Brown et al., "Genetic analysis of blood molecular phenotypes reveals common properties in the regulatory networks affecting complex traits," Nature Communications, vol. 14, no. 1, 2023.
[14]
I. B. Kotliar et al., "Itch receptor MRGPRX4 interacts with the receptor activity-modifying proteins," Journal of Biological Chemistry, vol. 299, no. 5, 2023.
[15]
J. Hauser et al., "Microfluidic Device for Patient-Centric Multiplexed Assays with Readout in Centralized Laboratories," Analytical Chemistry, vol. 95, no. 2, pp. 1350-1358, 2023.
[16]
F. Ribet et al., "Microneedle Patch for Painless Intradermal Collection of Interstitial Fluid Enabling Multianalyte Measurement of Small Molecules, SARS‐CoV‐2 Antibodies, and Protein Profiling," Advanced Healthcare Materials, vol. 12, no. 13, 2023.
[17]
L. Dahl et al., "Multiplexed selectivity screening of anti-GPCR antibodies," Science Advances, vol. 9, no. 18, 2023.
[18]
C. R. Cederroth et al., "Screening for Circulating Inflammatory Proteins Does Not Reveal Plasma Biomarkers of Constant Tinnitus," Journal of the Association for Research in Otolaryngology, vol. 24, no. 6, pp. 593-606, 2023.
[19]
S. Sendic et al., "Soluble CD14 and Osteoprotegerin Associate with Ankle-Brachial Index as a Measure of Arterial Stiffness in Patients with Mild-to-Moderate Chronic Kidney Disease in a Five-Year Prospective Study," CardioRenal Medicine, vol. 13, no. 1, pp. 189-201, 2023.
[20]
X. Yu et al., "Advances in plasma proteomics : Moving from technology to precision medicine," PROTEOMICS - Clinical Applications, vol. 16, no. 6, 2022.
[21]
C. E. Thomas et al., "Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer," Translational Oncology, vol. 17, pp. 101339, 2022.
[22]
A. Wesolowska-Andersen et al., "Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals : An IMI DIRECT study," Cell Reports Medicine, vol. 3, no. 1, 2022.
[23]
Z. Yang et al., "Genetic Landscape of the ACE2 Coronavirus Receptor," Circulation, vol. 145, no. 18, pp. 1398-1411, 2022.
[24]
R. Gurke et al., "Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis," Biomedicines, vol. 10, no. 10, 2022.
[25]
X. Yu et al., "Advances in plasma proteomics : Call for papers for an upcoming special issue," PROTEOMICS - Clinical Applications, vol. 15, no. 6, 2021.
[26]
M. Stockfelt et al., "Circulating proteins associated with allergy development in infants-an exploratory analysis," Clinical Proteomics, vol. 18, no. 1, 2021.
[27]
M. Zeybel et al., "Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients," Molecular Systems Biology, vol. 17, no. 10, 2021.
[28]
C. Wu et al., "Elevated circulating follistatin associates with an increased risk of type 2 diabetes," Nature Communications, vol. 12, no. 1, 2021.
[29]
M. J. Iglesias et al., "Identification of Endothelial Proteins in Plasma Associated With Cardiovascular Risk Factors," Arteriosclerosis, Thrombosis and Vascular Biology, vol. 41, no. 12, pp. 2990-3004, 2021.
[30]
A. Gummesson et al., "Longitudinal plasma protein profiling of newly diagnosed type 2 diabetes," EBioMedicine, vol. 63, 2021.
[31]
N. Roxhed et al., "Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2," Nature Communications, vol. 12, no. 1, 2021.
[32]
W. Bauer et al., "Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection," Viruses, vol. 13, no. 12, pp. 2456, 2021.
[33]
R. Bizzotto, J. M. Schwenk and A. Mari, "Processes Underlying Glycemic Deterioration in Type 2 Diabetes : An IMI DIRECT Study," Diabetes Care, vol. 44, no. 2, pp. 511-518, 2021.
[34]
A. Tura, J. M. Schwenk and A. Mari, "Profiles of Glucose Metabolism in Different Prediabetes Phenotypes, Classified by Fasting Glycemia, 2-Hour OGTT, Glycated Hemoglobin, and 1-Hour OGTT : An IMI DIRECT Study," Diabetes, vol. 70, no. 9, pp. 2092-2106, 2021.
[35]
E. W. Deutsch et al., "p Advances and Utility of the Human Plasma Proteome," Journal of Proteome Research, vol. 20, no. 12, pp. 5241-5263, 2021.
[36]
N. Bar et al., "A reference map of potential determinants for the human serum metabolome," Nature, vol. 588, no. 7836, pp. 135-140, 2020.
[37]
R. Eriksen, J. M. Schwenk and G. Frost, "Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk : An IMI DIRECT study," EBioMedicine, vol. 58, 2020.
[38]
Å. Sivertsson et al., "Enhanced Validation of Antibodies Enables the Discovery of Missing Proteins," Journal of Proteome Research, vol. 19, no. 12, pp. 4766-4781, 2020.
[39]
T. Dodig-Crnkovic et al., "Facets of individual-specific health signatures determined from longitudinal plasma proteome profiling," EBioMedicine, vol. 57, 2020.
[40]
K. Suhre, M. I. McCarthy and J. M. Schwenk, "Genetics meets proteomics : perspectives for large population-based studies," Nature reviews genetics, 2020.
[41]
T. Abdellah et al., "Integration of molecular profiles in a longitudinal wellness profiling cohort," Nature Communications, vol. 11, no. 1, 2020.
[42]
K. Drobin et al., "Molecular Profiling for Predictors of Radiosensitivity in Patients with Breast or Head-and-Neck Cancer," Cancers, vol. 12, no. 3, 2020.
[43]
M. Dezfouli et al., "Newborn Screening for Presymptomatic Diagnosis of Complement and Phagocyte Deficiencies," Frontiers in Immunology, vol. 11, 2020.
[44]
M. Obura et al., "Post-load glucose subgroups and associated metabolic traits in individuals with type 2 diabetes : An IMI-DIRECT study," PLOS ONE, vol. 15, no. 11, 2020.
[45]
N. Atabaki-Pasdar et al., "Predicting and elucidating the etiology of fatty liver disease : A machine learning modeling and validation study in the IMI DIRECT cohorts," PLoS Medicine, vol. 17, no. 6, 2020.
[46]
M.-G. Hong et al., "Profiles of histidine-rich glycoprotein associate with age and risk of all-cause mortality," Life Science Alliance, vol. 3, no. 10, pp. e202000817, 2020.
[47]
R. W. Koivula et al., "The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes : an IMI DIRECT study," Diabetologia, vol. 63, no. 4, pp. 744-756, 2020.
[48]
V. Gudmundsdottir et al., "Whole blood co-expression modules associate with metabolic traits and type 2 diabetes : an IMI-DIRECT study," Genome Medicine, vol. 12, no. 1, 2020.
[49]
W. Zhong et al., "Whole-genome sequence association analysis of blood proteins in a longitudinal wellness cohort," Genome Medicine, vol. 12, no. 1, 2020.
[50]
A. Andersson et al., "Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease," Clinica Chimica Acta, vol. 494, pp. 79-93, 2019.
[51]
R. W. Koivula, J. M. Schwenk and P. W. Franks, "Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes : descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium," Diabetologia, vol. 62, no. 9, pp. 1601-1615, 2019.
[52]
H. R. Wilman et al., "Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration," Journal of Hepatology, vol. 71, no. 3, pp. 594-602, 2019.
[53]
M. Pernemalm et al., "In-depth human plasma proteome analysis captures tissue proteins and transfer of protein variants across the placenta," eLIFE, vol. 8, 2019.
[54]
V. Ignjatovic et al., "Mass Spectrometry-Based Plasma Proteomics : Considerations from Sample Collection to Achieving Translational Data," Journal of Proteome Research, vol. 18, no. 12, pp. 4085-4097, 2019.
[55]
E. Lorenzen et al., "Multiplexed analysis of the secretin-like GPCR-RAMP interactome," Science Advances, vol. 5, no. 9, 2019.
[56]
G. S. Omenn et al., "Progress on Identifying and Characterizing the Human Proteome : 2019 Metrics from the HUPO Human Proteome Project," Journal of Proteome Research, vol. 18, no. 12, pp. 4098-4107, 2019.
[57]
F. Edfors et al., "Screening a Resource of Recombinant Protein Fragments for Targeted Proteomics," Journal of Proteome Research, vol. 18, no. 7, pp. 2706-2718, 2019.
[58]
R. S. Häussler et al., "Systematic Development of Sandwich Immunoassays for the Plasma Secretome," Proteomics, 2019.
[59]
C. Fredolini et al., "Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles," Scientific Reports, vol. 9, 2019.
[60]
K. Drobin et al., "Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci," Inflammatory Bowel Diseases, vol. 25, no. 2, pp. 306-316, 2019.
[61]
[62]
S. Byström et al., "Affinity proteomic profiling of plasma for proteins associated to area-based mammographic breast density," Breast Cancer Research, vol. 20, 2018.
[63]
[64]
D. Djureinovic et al., "Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer," Lung Cancer, 2018.
[65]
L. P. Matic et al., "Novel Multiomics Profiling of Human Carotid Atherosclerotic Plaques and Plasma Reveals Biliverdin Reductase B as a Marker of Intraplaque Hemorrhage," JACC: Basic to Translational Science, vol. 3, no. 4, pp. 464-480, 2018.
[66]
G. S. Omenn et al., "Progress on Identifying and Characterizing the Human Proteome : 2018 Metrics from the HUPO Human Proteome Project," Journal of Proteome Research, vol. 17, no. 12, pp. 4031-4041, 2018.
[67]
B. Glimelius et al., "U-CAN : a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden," Acta Oncologica, vol. 57, no. 2, pp. 187-194, 2018.
[68]
B. Omazic et al., "A Preliminary Report : Radical Surgery and Stem Cell Transplantation for the Treatment of Patients with Pancreatic Cancer," Journal of immunotherapy (1997), vol. 40, no. 4, pp. 132-139, 2017.
[69]
M. Uhlén et al., "A pathology atlas of the human cancer transcriptome," Science, vol. 357, no. 6352, pp. 660-+, 2017.
[70]
[71]
S. Byström et al., "Affinity Proteomics Exploration of Melanoma Identifies Proteins in Serum with Associations to T-Stage and Recurrence," Translational Oncology, vol. 10, no. 3, pp. 385-395, 2017.
[72]
L. Lourido et al., "Discovery of circulating proteins associated to knee radiographic osteoarthritis," Scientific Reports, vol. 7, 2017.
[73]
E. Pin et al., "Identification of a Novel Autoimmune Peptide Epitope of Prostein in Prostate Cancer," Journal of Proteome Research, vol. 16, no. 1, pp. 204-216, 2017.
[74]
H. Idborg et al., "PROTEIN PROFILING IN PLASMA REVEALS MOLECULAR SUBGROUPS IN SYSTEMIC LUPUS ERYTHEMATOSUS," Annals of the Rheumatic Diseases, vol. 76, pp. A52-A52, 2017.
[75]
J. M. Schwenk et al., "The Human Plasma Proteome Draft of 2017 : Building on the Human Plasma PeptideAtlas from Mass Spectrometry and Complementary Assays," Journal of Proteome Research, vol. 16, no. 12, pp. 4299-4310, 2017.
[76]
X. Zhou et al., "Thiol–ene–epoxy thermoset for low-temperature bonding to biofunctionalized microarray surfaces," Lab on a Chip, vol. 17, no. 21, pp. 3672-3681, 2017.
[77]
A. Zandian et al., "Untargeted screening for novel autoantibodies with prognostic value in first-episode psychosis," Translational Psychiatry, vol. 7, 2017.
[78]
A. Zandian et al., "Whole-Proteome Peptide Microarrays for Profiling Autoantibody Repertoires within Multiple Sclerosis and Narcolepsy," Journal of Proteome Research, vol. 16, no. 3, pp. 1300-1314, 2017.
[79]
U. Qundos et al., "Affinity proteomics discovers decreased levels of AMFR in plasma from Osteoporosis patients," PROTEOMICS - Clinical Applications, vol. 10, no. 6, pp. 681-690, 2016.
[80]
B. Ayoglu et al., "Anoctamin 2 identified as an autoimmune target in multiple sclerosis," Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 8, pp. 2188-2193, 2016.
[81]
B. Ayoglu, J. M. Schwenk and P. Nilsson, "Antigen arrays for profiling autoantibody repertoires," Bioanalysis, vol. 8, no. 10, pp. 1105-1126, 2016.
[82]
A. Häggmark-Månberg et al., "Autoantibody targets in vaccine-associated narcolepsy," Autoimmunity, vol. 49, no. 6, pp. 421-433, 2016.
[83]
J. Remnestål et al., "CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease," PROTEOMICS - Clinical Applications, vol. 10, no. 12, pp. 1242-1253, 2016.
[84]
C. Hamsten et al., "Elevated levels of FN1 and CCL2 in bronchoalveolar lavage fluid from sarcoidosis patients," Respiratory Research, vol. 17, 2016.
[85]
M. Mikus et al., "Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury," Liver international, vol. 37, no. 1, pp. 132-140, 2016.
[86]
R. Sjöberg et al., "Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling," New Biotechnology, vol. 33, no. 5, pp. 582-592, 2016.
[87]
C. Fredolini et al., "Immunocapture strategies in translational proteomics," Expert Review of Proteomics, vol. 13, no. 1, pp. 83-98, 2016.
[88]
M.-G. Hong et al., "Multidimensional Normalization to Minimize Plate Effects of Suspension Bead Array Data," Journal of Proteome Research, vol. 15, no. 10, pp. 3473-3480, 2016.
[89]
B. Ayoglu et al., "Multiplexed protein profiling by sequential affinity capture," Proteomics, vol. 16, no. 8, pp. 1251-1256, 2016.
[90]
A. Häggmark, J. M. Schwenk and P. Nilsson, "Neuroproteomic profiling of human body fluids," PROTEOMICS - Clinical Applications, vol. 10, no. 4, pp. 485-502, 2016.
[91]
M. Bruzelius et al., "PDGFB, a new candidate plasma biomarker for venous thromboembolism : Results from the VEREMA affinity proteomics study," Blood, vol. 128, no. 23, pp. e59-e66, 2016.
[92]
M. J. Iglesias et al., "An affinity proteomics study for plasma biomarker candidates of cardiovascular disease in venous thromboembolism," Journal of Thrombosis and Haemostasis, vol. 13, pp. 956-956, 2015.
[93]
G. O'Hurley et al., "Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer," PLOS ONE, vol. 10, no. 8, 2015.
[94]
P. Arner et al., "Circulating Carnosine Dipeptidase 1 associates with weight loss and poor prognosis in gastrointestinal cancer," PLOS ONE, vol. 10, no. 4, 2015.
[95]
C. Hamsten et al., "Heat differentiated complement factor profiling," Journal of Proteomics, vol. 126, pp. 155-162, 2015.
[96]
K. Papp et al., "Multiplex measurement of autoantibody levels and complement activation in rheumatoid arthritis," Molecular Immunology, vol. 67, no. 1, pp. 170-170, 2015.
[97]
A. Häggmark et al., "Proteomic Profiling Reveals Autoimmune Targets in Sarcoidosis," American Journal of Respiratory and Critical Care Medicine, vol. 191, no. 5, pp. 574-583, 2015.
[98]
M. Uhlén et al., "Tissue-based map of the human proteome," Science, vol. 347, no. 6220, pp. 1260419, 2015.
[99]
M. Bruzelius et al., "Verema - an affinity proteomics study to identify and translate plasma biomarkers for venous thromboembolism," Journal of Thrombosis and Haemostasis, vol. 13, pp. 954-954, 2015.
[100]
S. Byström et al., "Affinity Proteomic Profiling of Plasma, Cerebrospinal Fluid, and Brain Tissue within Multiple Sclerosis," Journal of Proteome Research, vol. 13, no. 11, pp. 4607-4619, 2014.
[101]
J. Bachmann et al., "Affinity Proteomics Reveals Elevated Muscle Proteins in Plasma of Children with Cerebral Malaria," PLoS Pathogens, vol. 10, no. 4, pp. e1004038, 2014.
[102]
B. Ayoglu et al., "Affinity proteomics within rare diseases : a BIO-NMD study for blood biomarkers of muscular dystrophies," EMBO Molecular Medicine, vol. 6, no. 7, pp. 918-936, 2014.
[103]
F. Henjes et al., "Analysis of Autoantibody Profiles in Osteoarthritis Using Comprehensive Protein Array Concepts," Journal of Proteome Research, vol. 13, no. 11, pp. 5218-5229, 2014.
[104]
U. Qundos et al., "Analysis of plasma from prostate cancer patients links decreased carnosine dipeptidase 1 levels to lymph node metastasis," Translational Proteomics, vol. 2, no. 1, pp. 14-24, 2014.
[105]
L. Fagerberg et al., "Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics," Molecular & Cellular Proteomics, vol. 13, no. 2, pp. 397-406, 2014.
[106]
A. N. Kremer et al., "Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation," Haematologica, vol. 99, no. 2, pp. 365-369, 2014.
[107]
M. Dezfouli et al., "Magnetic bead assisted labeling of antibodies at nanogram scale," Proteomics, vol. 14, no. 1, pp. 14-18, 2014.
[108]
M. Dezfouli et al., "Parallel barcoding of antibodies for DNA-assisted proteomics," Proteomics, vol. 14, no. 21-22, pp. 2432-2436, 2014.
[109]
A. Häggmark et al., "Plasma profiling revelas three proteins associated to amyotrophic lateral sclerosis," Annals of Clinical and Translational Neurology, vol. 1, no. 8, pp. 544-553, 2014.
[110]
A. Danielsson et al., "The Human Pancreas Proteome Defined by Transcriptomics and Antibody-Based Profiling," PLOS ONE, vol. 9, no. 12, pp. e115421, 2014.
[111]
A. Häggmark et al., "Antibody-based profiling of cerebrospinal fluid within multiple sclerosis," Proteomics, vol. 13, no. 15, pp. 2256-2267, 2013.
[112]
B. Ayoglu et al., "Autoantibody profiling in multiple sclerosis using arrays of human protein fragments," Molecular & Cellular Proteomics, vol. 12, no. 9, pp. 2657-2672, 2013.
[113]
L. Fagerberg et al., "Contribution of antibody-based protein profiling to the human chromosome-centric proteome project (C-HPP)," Journal of Proteome Research, vol. 12, no. 6, pp. 2439-2448, 2013.
[114]
K. Drobin, P. Nilsson and J. M. Schwenk, "Highly multiplexed antibody suspension bead arrays for plasma protein profiling," Methods in Molecular Biology, vol. 1023, pp. 137-145, 2013.
[115]
S. Darmanis et al., "Identification of Candidate Serum Proteins for Classifying Well-Differentiated Small Intestinal Neuroendocrine Tumors," PLOS ONE, vol. 8, no. 11, pp. e81712, 2013.
[116]
U. Qundos et al., "Profiling post-centrifugation delay of serum and plasma with antibody bead arrays," Journal of Proteomics, vol. 95, no. SI, pp. 46-54, 2013.
[117]
M. Neiman et al., "Selectivity analysis of single binder assays used in plasma protein profiling," Proteomics, vol. 13, no. 23-24, pp. 3406-3410, 2013.
[118]
A. Asplund et al., "Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research," Proteomics, vol. 12, no. 13, pp. 2067-2077, 2012.
[119]
K. Colwill et al., "A roadmap to generate renewable protein binders to the human proteome," Nature Methods, vol. 8, no. 7, pp. 551-8, 2011.
[120]
J. M. Schwenk and P. Nilsson, "Antibody suspension bead arrays," Methods in molecular biology (Clifton, N.J.), vol. 723, pp. 29-36, 2011.
[121]
A. Häggmark et al., "Classification of protein profiles from antibody microarrays using heat and detergent treatment.," New Biotechnology, vol. 29, no. 5, pp. 564-570, 2011.
[122]
B. Hjelm et al., "Generation of monospecific antibodies based on affinity capture of polyclonal antibodies," Protein Science, vol. 20, no. 11, pp. 1824-1835, 2011.
[123]
M. Neiman et al., "Plasma Profiling Reveals Human Fibulin-1 as Candidate Marker for Renal Impairment," Journal of Proteome Research, vol. 10, no. 11, pp. 4925-4934, 2011.
[124]
B. Ayoglu et al., "Systematic antibody and antigen-based proteomic profiling with microarrays," EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, vol. 11, no. 2, pp. 219-234, 2011.
[125]
F. Pontén et al., "The Human Protein Atlas as a proteomic resource for biomarker discovery," Journal of Internal Medicine, vol. 270, no. 5, pp. 428-446, 2011.
[126]
R. Sjöberg et al., "Validation of affinity reagents using antigen microarrays," New Biotechnology, vol. 29, no. 5, pp. 555-563, 2011.
[127]
B. S. Kato et al., "Variance decomposition of protein profiles from antibody arrays using a longitudinal twin model," Proteome Science, vol. 9, no. 1, pp. 73, 2011.
[128]
J. Gantelius et al., "A lateral flow protein microarray for rapid determination of contagious bovine pleuropneumonia status in bovine serum," Journal of Microbiological Methods, vol. 82, no. 1, pp. 11-18, 2010.
[129]
C. Eriksson et al., "Affibody molecule-mediated depletion of HSA and IgG using different buffer compositions : a 15 min protocol for parallel processing of 1-48 samples," Biotechnology and applied biochemistry, vol. 56, pp. 49-57, 2010.
[130]
J. M. Schwenk et al., "Comparative protein profiling of serum and plasma using an antibody suspension bead array approach," Proteomics, vol. 10, no. 3, pp. 532-540, 2010.
[131]
J. M. Schwenk et al., "Toward Next Generation Plasma Profiling via Heat-induced Epitope Retrieval and Array-based Assays," Molecular & Cellular Proteomics, vol. 9, no. 11, pp. 2497-2507, 2010.
[132]
K. Larsson et al., "Characterization of PrEST-based antibodies towards human Cytokeratin-17," JIM - Journal of Immunological Methods, vol. 342, pp. 20-32, 2009.
[133]
N. LeBlanc et al., "Development of a magnetic bead microarray for simultaneous and simple detection of four pestiviruses," Journal of Virological Methods, vol. 155, pp. 1-9, 2009.
[134]
J. Rockberg, J. M. Schwenk and M. Uhlén, "Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies," Molecular Oncology, vol. 3, no. 3, pp. 238-247, 2009.
[135]
J. Gantelius et al., "Magnetic bead-based detection of autoimmune responses using protein microarrays.," New biotechnology, vol. 26, pp. 269-276, 2009.
[136]
M. Neiman et al., "Multiplex Screening of Surface Proteins from Mycoplasma mycoides subsp mycoides Small Colony for an Antigen Cocktail Enzyme-Linked Immunosorbent Assay," Clinical and Vaccine Immunology, vol. 16, no. 11, pp. 1665-1674, 2009.
[137]
C. Hamsten et al., "Recombinant surface proteomics as a tool to analyze humoral immune responses in bovines infected by Mycoplasma mycoides subsp. mycoides SC," Molecular & Cellular Proteomics, vol. 8, no. 11, pp. 2544-2554, 2009.
[138]
R. Rimini et al., "Validation of serum protein profiles by a dual antibody array approach," , vol. 73, no. 2, pp. 252-266, 2009.
[139]
J. M. Schwenk et al., "Antibody suspension bead arrays within serum proteomics," Journal of Proteome Research, vol. 7, no. 8, pp. 3168-3179, 2008.
[140]
J. M. Schwenk et al., "Determination of binding specificities in highly multiplexed bead-based assays for antibody proteomics," Molecular & Cellular Proteomics, vol. 6, no. 1, pp. 125-132, 2007.
Conference papers
[141]
C. A. Rossi et al., "Longitudinal Relationships Between Proteomics and Beta-Cell Dysfunction in Type 2 Diabetes: an IMI Direct Study," in 8th National Congress of Bioengineering, GNB 2023 : Proceedings, 2023.
[142]
J. Hauser et al., "On-Chip Assay for Home-Sampling, Mail-Based Shipping and Centralized Laboratory Readout," in MicroTAS 2021 : 25th International Conference on Miniaturized Systems for Chemistry and Life Sciences, 2021, pp. 807-808.
Chapters in books
[143]
M. J. Iglesias, J. M. Schwenk and J. Odeberg, "Affinity Proteomics Assays for Cardiovascular and Atherosclerotic Disease Biomarkers," in Protein Microarrays for Disease Analysis : Methods and Protocols, : Springer Nature, 2021, pp. 163-179.
[144]
A. Bendes et al., "Bead-Based Assays for Validating Proteomic Profiles in Body Fluids," in Protein Microarrays for Disease Analysis : Methods and Protocols, : Springer Nature, 2021, pp. 65-78.
[145]
R. Sjöberg et al., "High-density antigen microarrays for the assessment of antibody selectivity and off-target binding," in Epitope Mapping Protocols, : Humana Press Inc., 2018, pp. 231-238.
[146]
B. Ayoglu, P. Nilsson and J. M. Schwenk, "Multiplexed antigen bead arrays for the assessment of antibody selectivity and epitope mapping," in Epitope Mapping Protocols, : Humana Press Inc., 2018, pp. 239-248.
[147]
E. Birgersson, J. . M. Schwenk and B. Ayoglu, "Bead-based and multiplexed immunoassays for protein profiling via sequential affinity capture," in Serum/Plasma Proteomics, : Humana Press, 2017, pp. 45-54.
[148]
C. Hellström et al., "High-density serum/plasma reverse phase protein arrays," in Serum/Plasma Proteomics, : Humana Press, 2017, pp. 229-238.
[149]
A. Häggmark-Månberg, P. Nilsson and J. Schwenk, "Neuroproteomic profiling of cerebrospinal fluid (CSF) by multiplexed affinity arrays," in Neuroproteomics : Methods and Protocols, : Humana Press, 2017, pp. 247-254.
[150]
J. M. Schwenk and P. Nilsson, "Assessment of antibody specificity using suspension bead arrays.," in Methods in Molecular Biology, : Springer, 2011, pp. 183-189.
Non-peer reviewed
Articles
[151]
T. D. Michalettou et al., "Dissecting the interplay between ageing, sex and body mass index on a molecular level," European Journal of Human Genetics, vol. 32, pp. 656-657, 2024.
[152]
[153]
C. Rossi et al., "Association between dynamics of circulating proteins and of beta cell function in type 2 diabetes : an IMI DIRECT study," Diabetologia, vol. 66, no. SUPPL 1, pp. S137-S138, 2023.
[154]
D. Davtian et al., "Discovery of Type 2 Diabetes genes using an accessible tissue," European Journal of Human Genetics, vol. 31, pp. 429-430, 2023.
[155]
C. E. Thomas et al., "Individual effects of gastric bypass surgery on longitudinal blood protein profiles : an IMI DIRECT study," Diabetologia, vol. 62, pp. S271-S271, 2019.
[156]
M. Persson et al., "Searching for Novel Autoantibodies with Clinical Relevance in Psychiatric Disorders," Schizophrenia Bulletin, vol. 44, pp. S120-S121, 2018.
[157]
D. Djureinovic et al., "Autoantibody Profiles of Cancer-Testis Genes in Non-Small Cell Lung Cancer," Journal of Thoracic Oncology, vol. 12, no. 11, pp. S2002-S2002, 2017.
[158]
L. Lourido et al., "IDENTIFICATION OF A SERUM PROTEIN BIOMARKER PANEL FOR THE DIAGNOSIS OF KNEE OSTEOARTHRITIS," Osteoarthritis and Cartilage, vol. 24, pp. S23-S23, 2016.
[159]
L. Lourido et al., "DISCOVERY OF POTENTIAL SERUM BIOMARKERS IN OSTEOARTHRITIS USING PROTEIN ARRAYS," Annals of the Rheumatic Diseases, vol. 74, pp. 373-374, 2015.
[160]
L. Lourido et al., "Discovery of Novel Serum Biomarkers for Osteoarthritis Using Affinity Proteomics," Arthritis & Rheumatology, vol. 67, 2015.
[161]
B. Ayoglu et al., "Proteomic profiling of the autoimmunity repertoire in multiple sclerosis," New Biotechnology, vol. 29, pp. S20-S20, 2012.
Other
[162]
J. Hauser et al., "A Microfluidic Device for Patient-Centric Multiplexed Assays with Readout in Centralized Laboratories," (Manuscript).
[163]
[164]
S. Byström et al., "Affinity proteomic profiling of plasma for proteins associated to mammographic breast density," (Manuscript).
[165]
S. Byström et al., "Affinity proteomics exploration of melanoma identifies proteins in serum with associations to T-stage and recurrence," (Manuscript).
[166]
[167]
M. Dezfouli et al., "Droplet-based Immuno-Sequencing to Deconvolute Affinity Recognition Events," (Manuscript).
[168]
R. Sjöberg et al., "Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling," (Manuscript).
[169]
U. Qundos et al., "Plasma levels of carnosine dipeptidase 1 decrease in prostate cancer patients with lymph node metastasis," (Manuscript).
[170]
B. Ayoglu et al., "The calcium-activated chloride channel anoctamine 2 as an autoimmune component of multiple sclerosis," (Manuscript).
[171]
M. Neiman et al., "Validating the selectivity of antibodies used in multiplexed serum profiling via parallel immunocapture analysis," (Manuscript).
Latest sync with DiVA:
2024-12-03 01:02:57